Repare Therapeutics Inc. (RPTX)

Repare Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018	2017
Revenue	51.13	131.83	7.6	0.14	0	0	0
Revenue Growth (YoY)	-61.21%	1634.61%	5529.63%	-	-	-	-
Gross Profit	51.13	131.83	7.6	0.14	0	0	0
Selling, General & Admin	33.76	32.56	26.21	14.35	5.38	2.91	1.77
Research & Development	133.59	119.07	90.05	40.09	21	9.91	4.4
Operating Expenses	167.36	151.63	116.26	54.44	26.38	12.82	6.18
Operating Income	-116.22	-19.8	-108.66	-54.3	-26.38	-12.82	-6.18
Other Expense / Income	-13.05	-5.9	-0.07	0.44	0.64	1.43	1.62
Pretax Income	-103.18	-13.9	-108.59	-54.74	-27.02	-14.25	-7.8
Income Tax	-9.38	15.15	-1.68	-1.33	0.2	0.04	0
Net Income	-93.8	-29.05	-106.91	-53.42	-27.22	-14.28	-7.8
Shares Outstanding (Basic)	42	42	38	20	2	2	2
Shares Outstanding (Diluted)	42	42	38	20	2	2	2
Shares Change	0.41%	10.85%	88.66%	1211.56%	-	0.38%	-
EPS (Basic)	-2.23	-0.69	-2.83	-2.66	-17.81	-9.35	-5.12
EPS (Diluted)	-2.23	-0.69	-2.83	-2.66	-17.81	-9.35	-5.12
Free Cash Flow	-129.1	-0.28	-87.45	-8.32	-19.73	-13.2	-7.16
Free Cash Flow Per Share	-3.07	-0.01	-2.31	-0.41	-12.91	-8.64	-4.71
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-227.30%	-15.02%	-1429.74%	-40223.70%	-	-	-
Profit Margin	-183.44%	-22.03%	-1406.68%	-39568.15%	-	-	-
Free Cash Flow Margin	-252.47%	-0.21%	-1150.61%	-6163.70%	-	-	-
EBITDA	-99.03	-9.72	-105.24	-52.96	-26.05	-13.84	-7.69
EBITDA Margin	-193.68%	-7.37%	-1384.76%	-39225.93%	-	-	-
Depreciation & Amortization	4.15	4.18	3.34	1.79	0.97	0.41	0.1
EBIT	-103.18	-13.9	-108.59	-54.74	-27.02	-14.25	-7.8
EBIT Margin	-201.79%	-10.54%	-1428.76%	-40549.63%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).